Pharmaseed in Parkinson’s Disease



Pharmaseed in Parkinson’s Disease

We are thrilled to announce that Pharmaseed was at the core basis of a treatment used during a successful phase IIb trial for Parkinson’s Disease led by Pharma Two B.
 

” Real translation is not just a phrase or a declaration”

 
This success confirm and reinforce our track record in translational research. Based on an invention by I. Lamensdorf and Y. Sela, a suitable pharmaceutical carrier and a fixed dose combination of two active agents were developed in our company.
 
The combination of the two agents was challenged on our Parkinson’s Disease animal pre-clinical model, within Pharmaseed facilities. Beyond pre-clinical testing, translational research implies that our experts balanced-out regulatory, intellectual property along with clinical needs.

 

We warmly congratulate Pharma Two B, and we hope that this new treatment will help Parkinson’s Disease patients.

 

 

Parkinson’s Disease_brochure#1

 

For more information on how we can help you
move your drug or device along the development pathway.
Contact Us